Andy Cloyd’s Post

View profile for Andy Cloyd, graphic

Co-founder & CEO at Superfiliate

Nothing like seeing your customers succeed! Even better its founded in good science that is helping people live longer, healthier lives. Congrats to Dennis Bernstein, Eric Venn-Watson MD, MBA, and the entire fatty15 team on their latest clinical trial The Journal of Nutrition released a report supporting that fatty15 can treat nutritional C15:0 deficiencies and reverse Cellular Fragility Syndrome. Cellular Fragility Syndrome, caused by low C15:0 levels, is the first nutritional deficiency syndrome to be identified in over 75 years. Studies support that Cellular Fragility Syndrome may be present in as many as 1 in 3 people, leading to accelerated aging and onset of aging-related conditions. The good news is that C15:0 nutritional deficiencies can be easily identified and treated. This randomized, double-blinded, and placebo-controlled trial included young adults (18 to 24 years old) and was led by UC San Diego. Here are the key findings from this important study: 1) 2 out of 3 study participants had C15:0 levels that met the criteria of nutritional C15:0 deficiency, 2) fatty15 safely and significantly raised C15:0 blood levels, and 3) those who achieved nutritionally sufficient C15:0 blood levels had clinically relevant evidence of reversing Cellular Fragility Syndrome, including improved liver function and red blood cell health. Go check out their awesome product! Link in comments!

To view or add a comment, sign in

Explore topics